title: Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities - Kenya, December 2013.
abstract: Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, circulation of indigenous wild poliovirus (WPV) has continued without interruption in only three countries: Afghanistan, Nigeria, and Pakistan. During April-December 2013, a polio outbreak caused by WPV type 1 (WPV1) of Nigerian origin resulted in 217 cases in or near the Horn of Africa, including 194 cases in Somalia, 14 cases in Kenya, and nine cases in Ethiopia (all cases were reported as of March 10, 2014). During December 14-18, 2013, Kenya conducted the first-ever campaign providing inactivated poliovirus vaccine (IPV) together with oral poliovirus vaccine (OPV) as part of its outbreak response. The campaign targeted 126,000 children aged ≤59 months who resided in Somali refugee camps and surrounding communities near the Kenya-Somalia border, where most WPV1 cases had been reported, with the aim of increasing population immunity levels to ensure interruption of any residual WPV transmission and prevent spread from potential new importations. A campaign evaluation and vaccination coverage survey demonstrated that combined administration of IPV and OPV in a mass campaign is feasible and can achieve coverage >90%, although combined IPV and OPV campaigns come at a higher cost than OPV-only campaigns and require particular attention to vaccinator training and supervision. Future operational studies could assess the impact on population immunity and the cost-effectiveness of combined IPV and OPV campaigns to accelerate interruption of poliovirus transmission during polio outbreaks and in certain areas in which WPV circulation is endemic.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Sheikh
authors.forename: Frederick
authors.initials: F
authors.lastname: Makokha
authors.forename: Abdullahi M
authors.initials: AM
authors.lastname: Hussein
authors.forename: Gedi
authors.initials: G
authors.lastname: Mohamed
authors.forename: Ondrej
authors.initials: O
authors.lastname: Mach
authors.forename: Kabir
authors.initials: K
authors.lastname: Humayun
authors.forename: Samuel
authors.initials: S
authors.lastname: Okiror
authors.forename: Leila
authors.initials: L
authors.lastname: Abrar
authors.forename: Orkhan
authors.initials: O
authors.lastname: Nasibov
authors.forename: John
authors.initials: J
authors.lastname: Burton
authors.forename: Ahmed
authors.initials: A
authors.lastname: Unshur
authors.forename: Kathleen
authors.initials: K
authors.lastname: Wannemuehler
authors.forename: Concepcion F
authors.initials: CF
authors.lastname: Estivariz
mesh_terms: D002675:Child, Preschool; D019538:Health Care Surveys; D006293:Health Promotion / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007630:Kenya; D011051:Poliomyelitis / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000627:therapeutic use*; D011055:Poliovirus Vaccine, Oral / Q000627:therapeutic use*; D015397:Program Evaluation; D012036:Refugees / Q000706:statistics & numerical data; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral